TrialSignal
Clinical trial intelligence report
A Phase I/II Study of Ruxolitinib With Front-Line Neoadjuvant and Post-Surgical Therapy in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT02713386
Status
COMPLETED
Phase
Phase I/II
Sponsor
NRG Oncology
Executive brief
Investment-Ready Snapshot
This clinical trial evaluates the safety and efficacy of ruxolitinib phosphate in combination with standard chemotherapy (paclitaxel and carboplatin) for patients with advanced-stage epithelial ovarian cancer. The study aims to determine if the addition of ruxolitinib improves progression-free survival compared to chemotherapy alone.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT02713386
Indication
Fallopian Tube Clear Cell Adenocarcinoma
Modality
small molecule
Target
Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Intervention
Carboplatin, Paclitaxel, Ruxolitinib Phosphate, Therapeutic Conventional Surgery
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.